Amy Zhang

Amy Zhang

Auto-generated profile, based on publicly available information

Amy Zhang

Stanford University School of Medicine, Palo Alto, California, United States

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
ELEmily C. Liang
Emily C. Liang
SDSimone E. Dekker
Simone E. Dekker
JSJean M. G. Sabile
Jean M. G. Sabile
STStefan Torelli
Stefan Torelli
AZAmy Zhang
Amy Zhang
LMLori Muffly
Lori Muffly
Measurable residual disease (MRD) is an adverse prognostic factor in adult patients with acute lymphoblastic leukemia (ALL) undergoing hematopoietic cell transplant (HCT). Next-generation sequencing (NGS) can detect MRD with a sensitivity of 10–6, but the prognostic value of NGS-based MRD in adult patients with ALL undergoing HCT remains minimally studied. To evaluate the prognostic value of NGS-based MRD in adult patients with ALL undergoing HCT, patients aged ≥18 years with ALL who underwent allogeneic HCT at Stanford University or Oregon Health & Science University between January 2014 and April 2021 and were evaluated for MRD using the NGS-based clonoSEQ assay were included in this study. MRD was assessed before HCT (MRDpre) and up to 1 year after HCT (MRDpost). Patients were followed up for leukemia relapse and survival for up to 2 years after HCT. In total, 158 patients had a trackable clonotype for MRD monitoring. The cumulative incidence of relapse was increased at all levels of MRDpre, including in patients who had low MRDpre of <10–4 (hazard ratio [HR], 3.56; 95% confidence interval [95% CI], 1.39-9.15). In multivariable analysis, MRDpre level remained significantly prognostic; however, detectable MRDpost was the strongest predictor of relapse (HR, 4.60; 95% CI, 3.01-7.02). In exploratory analyses limited to patients with B-cell ALL, the detection of post-HCT immunoglobulin H (IgH) MRD clonotypes, rather than non-IgH MRD clonotypes, was associated with relapse. In this analysis across 2 large transplant centers, we found that the detection of MRD by NGS at a level of 10–6 offers significant prognostic value in adults with ALL undergoing HCT.

23 April 2026 in Blood
Verified
Journal Article
Closed access
PDF file
HSHrishikesh Krishna Srinagesh
Hrishikesh Krishna Srinagesh
VGVishal K. Gupta
Vishal K. Gupta
AZAmy Zhang
Amy Zhang
MGMichael R Grunwald
Michael R Grunwald
MCMatthew P Connor
Matthew P Connor
LMLori S. Muffly
Lori S. Muffly
In a real-world analysis of brexucabtagene autoleucel recipients with relapsed/refractory B-cell acute lymphoblastic leukemia (N = 278), lack of response to prior blinatumomab correlates with significantly worse following chimeric antigen receptor T-cell therapy outcomes.

25 June 2026 in Blood Advances
Verified
Journal Article
Open access
TOTamer Othman
Tamer Othman
GRGregory Roloff
Gregory Roloff
KMKatharine Miller
Katharine Miller
AZAmy Zhang
Amy Zhang
KSKatherine C. Sutherland
Katherine C. Sutherland
IAIbrahim Aldoss
Ibrahim Aldoss
Brexucabtagene-autoleucel (brexu-cel) produces high rates of measurable residual disease-negative (MRD-) complete response (CR) in adults with Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL); however, subsequent relapses remain frequent. It is unclear whether maintenance with tyrosine kinase inhibitors (TKIs) can enhance remission durability. We evaluated outcomes among adults with relapsed/refractory Ph+ ALL who received commercial brexu-cel and achieved MRD- CR across 19 U.S. institutions. Considering TKI maintenance as a time-varying covariate, we analyzed outcomes based on receipt of subsequent TKI maintenance versus no maintenance. Patients receiving consolidative transplantation or non-TKI maintenance were excluded. Fifty-one patients were included: 20 received TKI maintenance and 31 received no maintenance. The use of TKI maintenance was associated with a significantly lower 1-year cumulative incidence of relapse (HR 0.12; 95% CI, 0.02-0.88; p=0.037) which translated into improved progression-free survival (PFS, HR 0.19; 95% CI, 0.04-0.85; p=0.029) and a trend towards improved overall survival (OS, HR 0.34; 95% CI, 0.07-1.62; p=0.18). There was no difference in non-relapse mortality (NRM, HR 0.83; 95% CI, 0.12-5.87; p=0.85). This real-world analysis supports the administration of TKI maintenance in Ph+ ALL following achievement of MRD- CR with brexu-cel as a strategy to improve PFS following chimeric antigen receptor T cell therapy.

24 June 2026 in Blood Advances
Verified
Journal Article
Open access
CLCatherine Thuy Khanh Le
Catherine Thuy Khanh Le
AZAmy Zhang
Amy Zhang
RVRutu D Vyas
Rutu D Vyas
JOJoanne Otani
Joanne Otani
KRKathryn Russell
Kathryn Russell
ELEmily C. Liang
Emily C. Liang
Relapse in the central nervous system (CNS) is a devastating outcome in acute lymphoblastic leukemia (ALL). Allogeneic hematopoietic cell transplantation (HCT) in ALL is reserved for patients with high-risk and/or relapsed/refractory disease. However, there is a paucity of data describing the incidence and factors associated with post-HCT CNS relapse in the modern era. In this multicenter retrospective study of adults with ALL who underwent first HCT between 2011 and 2021 at Stanford Health Care (SHC) or University of Washington/Fred Hutch Cancer Center (UW/FH), we aimed to describe the incidence of post-HCT CNS relapse, factors associated with post-HCT CNS relapse, and the impact of CNS relapse on overall survival (OS). A total of 636 patients were included. The 1- and 3-year cumulative incidences of CNS relapse after HCT were 3% and 6%, respectively. Absence of CNS involvement prior to HCT, pre-HCT MRD negativity, and receipt of TBI-based conditioning were significantly associated with decreased risk of post-HCT CNS relapse. These three characteristics defined a composite low-risk group that was associated with lower risk of post-HCT relapse [HR = 0.31 (95% CI, 0.15-0.68), p = 0.0032]. Post-HCT CNS relapse was significantly associated with shorter overall survival [HR 7.33 (95% CI, 5.12-10.49), p < 0.0001]; worse outcomes were seen with earlier post-HCT CNS relapse. Future studies will be needed to assess if this low-risk group may benefit from de-escalation of CNS-directed interventions during HCT.

8 August 2012 in arXiv
Verified
Preprint
Open access
PDF file
AZAmy Zhang
Amy Zhang
NFNadia Fawaz
Nadia Fawaz
SIStratis Ioannidis
Stratis Ioannidis
AMAndrea Montanari
Andrea Montanari
It is often the case that, within an online recommender system, multiple users share a common account. Can such shared accounts be identified solely on the basis of the user- provided ratings? Once a shared account is identified, can the different users sharing it be identified as well? Whenever such user identification is feasible, it opens the way to possible improvements in personalized recommendations, but also raises privacy concerns. We develop a model for composite accounts based on unions of linear subspaces, and use subspace clustering for carrying out the identification task. We show that a significant fraction of such accounts is identifiable in a reliable manner, and illustrate potential uses for personalized recommendation.

9 September 2026 in The Oncologist
Verified
Journal Article
Open access
SGSamuel Greenwald
Samuel Greenwald
MHMuna Hassan
Muna Hassan
LMLori Muffly
Lori Muffly
KMKate Miller
Kate Miller
JLJerry Luo
Jerry Luo
HPHelen M Parsons
Helen M Parsons
Adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) experience inferior survival relative to children. As access barriers may increase outcome disparities, we conducted a secret-shopper study to identify logistical burdens when initiating care for AYAs. We developed scripts describing hypothetical AYAs with ALL seeking initial oncology appointments and, from February 2024 to March 2025, used data from population-based cancer registries to call facilities treating AYAs with ALL. Outcomes included number of attempts (up to 3) and transfers, call time, and required documentation for scheduling. Data were summarized descriptively. Of 424 facilities, 276 could schedule oncology appointments via phone. Of these, 36.2% required ≥2 attempts. Across attempts, 43.5% required ≥2 transfers. Median call time was 8 minutes, but 19.6% of facilities required ≥15 minutes. Only 20.7% would schedule without a referral or medical records. AYAs with ALL face logistical burdens when scheduling appointments, requiring additional efforts to streamline care.